Bristol Myers Squibb (BMY) Stock Price, News & Analysis

Company Overview

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions. Notable products developed or marketed by the company include immune checkpoint inhibitors and combination oncology regimens, anticoagulant therapies, and immunomodulatory agents. The company maintains a sizable R&D organization and invests in clinical development, translational science and collaborative research to expand indications for existing therapies and to advance novel modalities such as targeted agents and cell‑based approaches.

The modern Bristol Myers Squibb was formed through the 1989 merger of Bristol‑Myers and Squibb, and it expanded materially with the acquisition of Celgene in 2019, which significantly broadened its hematology and oncology franchise and added a substantial product and pipeline base. BMS has a history of pursuing strategic licensing agreements, partnerships and acquisitions to complement internal discovery efforts and to access new technologies and therapeutic candidates.

BMS operates globally, serving patients and healthcare systems across North America, Europe, Asia and other regions through direct commercial operations and partner networks. The company is led by a senior executive team responsible for corporate strategy, R&D and global operations; as of the most recent public disclosures the company’s chief executive officer is Giovanni Caforio. Bristol Myers Squibb continues to prioritize innovation, regulatory engagement and collaborations with academic and industry partners to address unmet medical needs.

Key Stats

• Today's Range: $56.36 to $57.40
• 50-Day Range: $56.56 to $62.39
• 52-Week Range: $42.52 to $62.89
• Volume: 10.44 million shs
• Average Volume: 10.04 million shs
• Market Capitalization: $115.49 billion
• P/E Ratio: 15.89
• Dividend Yield: 4.46%
• Price Target: $61.31
• Consensus Rating: Hold

Bristol Myers Squibb Stock Analysis - MarketRank™

Bristol Myers Squibb scored higher than 95% of companies evaluated by MarketBeat, and ranked 37th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Hold

Consensus Rating

Bristol Myers Squibb has received a consensus rating of Hold. The company's average rating score is 2.37, and is based on no strong buy ratings, 8 buy ratings, 10 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Bristol Myers Squibb is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Bristol Myers Squibb has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: -3.82%

Earnings Growth

Earnings for Bristol Myers Squibb are expected to decrease by -3.82% in the coming year, from $6.29 to $6.05 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bristol Myers Squibb is 15.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.23.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bristol Myers Squibb is 15.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.35.

Price to Earnings Growth Ratio

Bristol Myers Squibb has a PEG Ratio of 0.16. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Bristol Myers Squibb has a P/B Ratio of 5.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.59% of the float of Bristol Myers Squibb has been sold short.

Short Interest Ratio / Days to Cover

Bristol Myers Squibb has a short interest ratio ("days to cover") of 3.42, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bristol Myers Squibb has recently increased by 2.83%, indicating that investor sentiment is decreasing.

Dividend

• Score: 5.0 / 5
• Dividend Strength: Strong

Dividend Leadership

Bristol Myers Squibb is a leading dividend payer. It pays a dividend yield of 4.42%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Bristol Myers Squibb has been increasing its dividend for 17 years.

Dividend Coverage

The dividend payout ratio of Bristol Myers Squibb is 70.79%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Bristol Myers Squibb will have a dividend payout ratio of 41.65% next year. This indicates that Bristol Myers Squibb will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.93

News Sentiment

Bristol Myers Squibb has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 80 news articles for Bristol Myers Squibb this week, compared to 13 articles on an average week.

Search Interest

89 people have searched for BMY on MarketBeat in the last 30 days. This is an increase of 24% compared to the previous 30 days.

MarketBeat Follows

54 people have added Bristol Myers Squibb to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Bristol Myers Squibb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,850,100.00 in company stock.

Percentage Held by Insiders

0.05% of the stock of Bristol Myers Squibb is held by insiders.

Percentage Held by Institutions

76.41% of the stock of Bristol Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BMY Stock Analysis - Frequently Asked Questions

How have BMY shares performed this year?

Bristol Myers Squibb's stock was trading at $53.93 on January 1st, 2026. Since then, BMY stock has increased by 4.9% and is now trading at $56.5560.

How were Bristol Myers Squibb's earnings last quarter?

Bristol Myers Squibb Company (NYSE:BMY) released its earnings results on Thursday, April, 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. The business's quarterly revenue was up 2.6% on a year-over-year basis.
Read the conference call transcript.

When did Bristol Myers Squibb's stock split?

Shares of Bristol Myers Squibb split on Thursday, June 26th 2014.The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were issued to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Does Bristol Myers Squibb have any subsidiaries?

Bristol Myers Squibb subsidiaries include MyoKardia, Forbius, Celgene, IFM Therapeutics, Cormorant Pharmaceuticals, Padlock Therapeutics, Cardioxyl Pharmaceuticals, and others.

Who are Bristol Myers Squibb's major shareholders?

Top institutional investors of Bristol Myers Squibb include Bank of New York Mellon Corp (1.14%), Pzena Investment Management LLC (0.84%), SG Americas Securities LLC (0.44%) and California Public Employees Retirement System (0.26%). Insiders that own company stock include David V Elkins, Samit Hirawat, Christopher S Boerner, Theodore R Samuels II, Ann Powell, Phil M Holzer, Benjamin Hickey, Robert M Plenge and Bartie Wendy Short.
View institutional ownership trends.

How do I buy shares of Bristol Myers Squibb?

Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bristol Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bristol Myers Squibb investors own include Chevron (CVX), Comcast (CMCSA), McKesson (MCK), Charles Schwab (SCHW), Edwards Lifesciences (EW), Yum! Brands (YUM) and Toronto Dominion Bank (TD).

Company Calendar

• Record date for 5/1 Dividend: 4/02/2026
• Ex-Dividend for 5/1 Dividend: 4/02/2026
• Last Earnings: 4/30/2026
• Dividend Payable: 5/01/2026
• Today: 5/06/2026
• Bank of America Global Healthcare Conference 2026: 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:BMY
• CIK: 14272
• Web: www.bms.com
• Phone: (212) 546-4000
• Fax: 212-546-4020
• Employees: 32,500
• Year Founded: 1887

Price Target and Rating

• Average Price Target for Bristol Myers Squibb: $61.31
• High Price Target: $75.00
• Low Price Target: $40.00
• Potential Upside/Downside: +8.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.37
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.56
• Trailing P/E Ratio: 15.89
• Forward P/E Ratio: 8.99
• P/E Growth: 0.16
• Net Income: $7.05 billion
• Net Margins: 15.01%
• Pretax Margin: 19.80%
• Return on Equity: 64.87%
• Return on Assets: 13.16%

Debt

• Debt-to-Equity Ratio: 2.10
• Current Ratio: 1.42
• Quick Ratio: 1.28

Sales & Book Value

• Annual Sales: $48.19 billion
• Price / Sales: 2.40
• Cash Flow: $8.08 per share
• Price / Cash Flow: 7.00
• Book Value: $9.84 per share
• Price / Book: 5.75

Miscellaneous

• Outstanding Shares: 2,042,070,000
• Free Float: 2,041,050,000
• Market Cap: $115.49 billion
• Optionable: Optionable
• Beta: 0.26